Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation

被引：0
|
作者：
Kumar, Aravid S. Ravi [1 ]
Hofman, Michael S. [1 ]
机构：
[1] Univ Melbourne, Peter MacCallum Ctr Melbourne, Prostate Canc Theranost & Imaging Ctr Excellence, Mol Imaging & Therapeut Nucl Med Canc Imaging, Melbourne, Vic, Australia
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 01期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
SAFETY;
D O I：
10.2967/jnumed.123.266638
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [41] Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Gafita, Andrei
    Wang, Hui
    Tauber, Robert
    D'Alessandria, Calogero
    Weber, Wolfgang A.
    Eiber, Matthias
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (10) : 2212 - 2213
  • [42] Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer
    Eiber, Matthias
    Heck, Matthias
    Tauber, Robert
    Rauscher, Isabel
    D'Alessandria, Calogero
    Maurer, Tobias
    Retz, Margitta
    Wester, Hans
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [43] Clinical impact of changes in tumor uptake on PSMAPET/CT during 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Djaileb, L.
    Farolfi, A.
    Rauscher, I.
    Fendler, W.
    Hadaschik, B.
    Rowe, S.
    Herrmann, K.
    Solnes, L.
    Rettig, M.
    Weber, M.
    Czernin, J.
    Calais, J.
    Benz, M.
    Eiber, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S196 - S196
  • [44] Initial experience with 177Lu-PSMA therapy for patients with advanced liver cancer
    Assadi, M.
    Rekabpour, S.
    Jafari, E.
    Shakibazad, N.
    Ahmadzadehfar, H.
    Alipour, Z.
    Amini, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S693 - S693
  • [45] Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters
    Aksu, Aysegul
    Topuz, Ozge Vural
    Yilmaz, Burcak
    Sen, Nazli Pinar Karahan
    Acar, Emine
    Kaya, Gamze Capa
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (04) : 468 - 474
  • [46] Safety and dosimetry of 177Lu-PSMA radioligand therapy among patients with a single kidney as compared to patients with both kidneys with or without renal insufficiency before treatment
    Zhang, J.
    Schuchardt, C.
    Kulkarni, H. R.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S646 - S647
  • [47] Impact of cross-irradiation on single time-point dosimetry in 177Lu-PSMA therapy
    Vergnaud, L.
    Badel, J.
    Giraudet, A.
    Sarrut, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S804 - S804
  • [48] Dosimetry and safety of 177Lu-PSMA radioligand therapy among patients with a single kidney as compared to patients with both kidneys with or without baseline renal insufficiency (RI)
    Zhang, Jingjing
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [49] Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
    Kind, Felix
    Eder, Ann-Christin
    Jilg, Cordula A.
    Hartrampf, Philipp E.
    Meyer, Philipp T.
    Ruf, Juri
    Michalski, Kerstin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) : 605 - 610
  • [50] Lu177 PSMA Radioligand Therapy: In vivo SPECT/CT quantitation
    Keidar, Zohar
    Lugassil, Rachel
    Raysberg, Elyahu
    Frenkel, Alex
    Kennedyl, John
    Israeli, Ora
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
12345